毒理性
◉ 母乳喂养期间使用概述：Zuclopenthixol 在美国尚未获得食品药品监督管理局的批准上市，但在其他国家可用。有限的信息表明，母亲每天口服剂量高达50毫克或每两周注射72毫克的储库型注射剂，在母乳中产生的水平较低，在哺乳婴儿中没有发现可察觉的短期不良效应。没有长期数据。一项国际指南建议服用zuclopenthixol的母亲不要哺乳。然而，一个安全评分系统发现zuclopenthixol在哺乳期间可以谨慎使用。在获得更多数据之前，zuclopenthixol应在哺乳期间仔细监测婴儿的情况下使用。
◉ 对哺乳婴儿的影响：六位妇女在哺乳期间接受了zuclopenthixol治疗。其中5位妇女每天口服4至50毫克，1位每两周接受72毫克的储库型注射剂。他们的哺乳婴儿年龄从3天到10个月不等，其中5位婴儿年龄在2个月以下。没有立即出现如婴儿嗜睡等不良效应。
◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。
◉ Summary of Use during Lactation:Zuclopenthixol is not approved for marketing in the United States, by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal oral doses of up to 50 mg daily or depot injections of 72 mg every 2 weeks produce low levels in breastmilk and no detectable short-term adverse effects in the breastfed infants. No long-term data are available. One international guideline recommends that women taking zuclopenthixol not breastfeed. However, a safety scoring system finds zuclopenthixol possible to use cautiously during breastfeeding. Until more data are available, zuclopenthixol should be used with careful infant monitoring during breastfeeding.
◉ Effects in Breastfed Infants:Six women received zuclopenthixol during nursing. Five of the women were receiving 4 to 50 mg daily by mouth and one was receiving a depot injection of 72 mg every 2 weeks. Their breastfed infants ranged in age from 3 days to 10 months old, 5 of whom were 2 months or under. No immediate adverse effects such infant drowsiness were noted.
◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)
